Cargando…
Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures
PURPOSE: There is scarce comparative effectiveness research on the new treatment modalities for localized prostate cancer. We aim to compare through Patient-Reported Outcome Measures (PROMs) the impact of active surveillance, robot-assisted radical prostatectomy (RARP), intensity-modulated radiother...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663757/ https://www.ncbi.nlm.nih.gov/pubmed/38021091 http://dx.doi.org/10.1016/j.ctro.2023.100694 |
_version_ | 1785138469034524672 |
---|---|
author | Zamora, Víctor Garin, Olatz Suárez, José Francisco Gutiérrez, Cristina Guedea, Ferran Cabrera, Patricia Castells, Manuel Herruzo, Ismael Fumadó, Lluis Samper, Pilar Ferrer, Carlos Regis, Lucas Pont, Àngels Ferrer, Montse |
author_facet | Zamora, Víctor Garin, Olatz Suárez, José Francisco Gutiérrez, Cristina Guedea, Ferran Cabrera, Patricia Castells, Manuel Herruzo, Ismael Fumadó, Lluis Samper, Pilar Ferrer, Carlos Regis, Lucas Pont, Àngels Ferrer, Montse |
author_sort | Zamora, Víctor |
collection | PubMed |
description | PURPOSE: There is scarce comparative effectiveness research on the new treatment modalities for localized prostate cancer. We aim to compare through Patient-Reported Outcome Measures (PROMs) the impact of active surveillance, robot-assisted radical prostatectomy (RARP), intensity-modulated radiotherapy (IMRT), and real-time brachytherapy, considering side effects (incontinence, irritative/obstructive urinary symptoms, sexual dysfunction and bowel symptoms) and physical and mental health. MATERIALS AND METHODS: Prospective cohort of men diagnosed with clinically localized prostate cancer (age 50-75y, T1-T2, and low risk including Gleason 3 + 4 in T1c) from 18 Spanish hospitals, followed up to 24 months. Treatment decisions were jointly made by patients and physicians (n = 572). The Expanded Prostate cancer Index Composite (EPIC-26) and Short-Form 36 (SF-36v2) were administered through telephone interviews before and three, six, 12, and 24 months after treatment. To account for correlation among repeated measures, generalized estimating equation models were constructed. All analyses were performed with propensity score weights to solve treatment selection bias. RESULTS: The PROMs completion rate at 24 months was 95.0 %. Active surveillance entails the fewest side effects, but with significant sexual (0.4 standard deviations [SD], p < 0.001) and physical health deterioration (0.5 SD, p < 0.001); and moderate mental health improvement (0.4 SD, p = 0.001) at 24 months. Compared with active surveillance, RARP presented greater urinary incontinence (p = 0.030), and IMRT and real-time brachytherapy worse bowel symptoms (p = 0.027 and p = 0.007) at 24 months. CONCLUSIONS: Most side effects of the new treatment modalities seem to be limited to short-term deteriorations, except for moderate-large urinary incontinence in patients who had undergone RARP and moderate bowel deterioration in patients treated with IMRT or with real-time brachytherapy. Furthermore, patients under active surveillance, IMRT, and real-time brachytherapy showed a moderate improvement in mental health. |
format | Online Article Text |
id | pubmed-10663757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106637572023-10-29 Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures Zamora, Víctor Garin, Olatz Suárez, José Francisco Gutiérrez, Cristina Guedea, Ferran Cabrera, Patricia Castells, Manuel Herruzo, Ismael Fumadó, Lluis Samper, Pilar Ferrer, Carlos Regis, Lucas Pont, Àngels Ferrer, Montse Clin Transl Radiat Oncol Original Research Article PURPOSE: There is scarce comparative effectiveness research on the new treatment modalities for localized prostate cancer. We aim to compare through Patient-Reported Outcome Measures (PROMs) the impact of active surveillance, robot-assisted radical prostatectomy (RARP), intensity-modulated radiotherapy (IMRT), and real-time brachytherapy, considering side effects (incontinence, irritative/obstructive urinary symptoms, sexual dysfunction and bowel symptoms) and physical and mental health. MATERIALS AND METHODS: Prospective cohort of men diagnosed with clinically localized prostate cancer (age 50-75y, T1-T2, and low risk including Gleason 3 + 4 in T1c) from 18 Spanish hospitals, followed up to 24 months. Treatment decisions were jointly made by patients and physicians (n = 572). The Expanded Prostate cancer Index Composite (EPIC-26) and Short-Form 36 (SF-36v2) were administered through telephone interviews before and three, six, 12, and 24 months after treatment. To account for correlation among repeated measures, generalized estimating equation models were constructed. All analyses were performed with propensity score weights to solve treatment selection bias. RESULTS: The PROMs completion rate at 24 months was 95.0 %. Active surveillance entails the fewest side effects, but with significant sexual (0.4 standard deviations [SD], p < 0.001) and physical health deterioration (0.5 SD, p < 0.001); and moderate mental health improvement (0.4 SD, p = 0.001) at 24 months. Compared with active surveillance, RARP presented greater urinary incontinence (p = 0.030), and IMRT and real-time brachytherapy worse bowel symptoms (p = 0.027 and p = 0.007) at 24 months. CONCLUSIONS: Most side effects of the new treatment modalities seem to be limited to short-term deteriorations, except for moderate-large urinary incontinence in patients who had undergone RARP and moderate bowel deterioration in patients treated with IMRT or with real-time brachytherapy. Furthermore, patients under active surveillance, IMRT, and real-time brachytherapy showed a moderate improvement in mental health. Elsevier 2023-10-29 /pmc/articles/PMC10663757/ /pubmed/38021091 http://dx.doi.org/10.1016/j.ctro.2023.100694 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Article Zamora, Víctor Garin, Olatz Suárez, José Francisco Gutiérrez, Cristina Guedea, Ferran Cabrera, Patricia Castells, Manuel Herruzo, Ismael Fumadó, Lluis Samper, Pilar Ferrer, Carlos Regis, Lucas Pont, Àngels Ferrer, Montse Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures |
title | Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures |
title_full | Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures |
title_fullStr | Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures |
title_full_unstemmed | Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures |
title_short | Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures |
title_sort | comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663757/ https://www.ncbi.nlm.nih.gov/pubmed/38021091 http://dx.doi.org/10.1016/j.ctro.2023.100694 |
work_keys_str_mv | AT zamoravictor comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT garinolatz comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT suarezjosefrancisco comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT gutierrezcristina comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT guedeaferran comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT cabrerapatricia comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT castellsmanuel comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT herruzoismael comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT fumadolluis comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT samperpilar comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT ferrercarlos comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT regislucas comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT pontangels comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT ferrermontse comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures AT comparativeeffectivenessofnewtreatmentmodalitiesforlocalizedprostatecancerthroughpatientreportedoutcomemeasures |